CN103203013A - 包含高氧亲和力的修饰血红蛋白的氧气输送方法和组合物 - Google Patents

包含高氧亲和力的修饰血红蛋白的氧气输送方法和组合物 Download PDF

Info

Publication number
CN103203013A
CN103203013A CN2013100910214A CN201310091021A CN103203013A CN 103203013 A CN103203013 A CN 103203013A CN 2013100910214 A CN2013100910214 A CN 2013100910214A CN 201310091021 A CN201310091021 A CN 201310091021A CN 103203013 A CN103203013 A CN 103203013A
Authority
CN
China
Prior art keywords
hemoglobin
blood
compositions
oxygen
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013100910214A
Other languages
English (en)
Chinese (zh)
Inventor
R·M·温斯洛
K·D·万得格里夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangart Inc
Original Assignee
Sangart Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangart Inc filed Critical Sangart Inc
Publication of CN103203013A publication Critical patent/CN103203013A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
CN2013100910214A 2002-01-11 2003-01-10 包含高氧亲和力的修饰血红蛋白的氧气输送方法和组合物 Pending CN103203013A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34774102P 2002-01-11 2002-01-11
US60/347,741 2002-01-11
US10/114,400 2002-04-01
US10/114,400 US20030153491A1 (en) 2002-01-11 2002-04-01 Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN038036487A Division CN1630527B (zh) 2002-01-11 2003-01-10 包含高氧亲和力的修饰血红蛋白的氧气输送方法和组合物

Publications (1)

Publication Number Publication Date
CN103203013A true CN103203013A (zh) 2013-07-17

Family

ID=26812138

Family Applications (2)

Application Number Title Priority Date Filing Date
CN038036487A Expired - Fee Related CN1630527B (zh) 2002-01-11 2003-01-10 包含高氧亲和力的修饰血红蛋白的氧气输送方法和组合物
CN2013100910214A Pending CN103203013A (zh) 2002-01-11 2003-01-10 包含高氧亲和力的修饰血红蛋白的氧气输送方法和组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN038036487A Expired - Fee Related CN1630527B (zh) 2002-01-11 2003-01-10 包含高氧亲和力的修饰血红蛋白的氧气输送方法和组合物

Country Status (15)

Country Link
US (3) US20030153491A1 (enExample)
EP (1) EP1465643B1 (enExample)
JP (2) JP5149480B2 (enExample)
KR (1) KR100964604B1 (enExample)
CN (2) CN1630527B (enExample)
AT (1) ATE382358T1 (enExample)
AU (1) AU2003207504B2 (enExample)
BR (1) BR0306846A (enExample)
CA (1) CA2473662C (enExample)
DE (1) DE60318388T2 (enExample)
DK (1) DK1465643T3 (enExample)
ES (1) ES2299686T3 (enExample)
MX (1) MXPA04006733A (enExample)
PT (1) PT1465643E (enExample)
WO (1) WO2003059363A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499732A (zh) * 2020-04-22 2020-08-07 中国科学院过程工程研究所 一种基于双重化学修饰的血红蛋白氧载体及其制备方法和应用
CN112188865A (zh) * 2018-05-11 2021-01-05 斯佩克卓尼克斯股份有限公司 异常血氧合水平监测系统和方法及自监测氧合系统和方法
CN114617957A (zh) * 2022-03-10 2022-06-14 中国人民解放军军事科学院军事医学研究院 羟乙基淀粉血红蛋白偶联物及其制备方法与应用

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
ES2360215T3 (es) * 2002-12-23 2011-06-01 Albert Einstein College Of Medicine Of Yeshiva University Hemoglobinas pegiladas no hipertensivas y sus procedimientos de preparación.
WO2004060965A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
WO2005056636A2 (en) 2003-12-03 2005-06-23 Nektar Therapeutics Al, Corporation Method of preparing maleimide functionalized polymers
MX2007002187A (es) * 2004-08-31 2007-10-08 Sangart Inc Metodos para mejorar la estabilidad hemodinamica utilizando composiciones que contienen oxigeno.
US8455437B2 (en) * 2005-02-04 2013-06-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method to predict and prevent oxygen-induced inflammatory tissue injury
AU2006220548B2 (en) 2005-03-07 2011-04-21 Sangart, Inc. Composition and methods for delivering carbon monoxide (CO) and nitric ozide (NO) CO to tissue using heme proteins as carriers
WO2007050121A2 (en) * 2005-05-11 2007-05-03 Albert Einstein College Of Medicine Of Yeshiva University Site specific pegylated hemoglobin, method of preparing same, and uses thereof
WO2006135740A1 (en) * 2005-06-10 2006-12-21 Albert Einstein College Of Medicine Of Yeshiva University Pegylated hemoglobin and albumin and uses thereof
US8071546B2 (en) * 2005-06-10 2011-12-06 La Jolla Bioengineering Institute Uses of pegylated albumin
CA2614987C (en) 2005-07-19 2013-10-08 Nektar Therapeutics Al, Corporation Method for preparing polymer maleimides
EP2463294B1 (en) 2006-05-22 2016-10-19 The Regents of The University of California Compositions and methods for the delivery of nitric oxide
US7504377B2 (en) * 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
CN101158676B (zh) * 2006-12-31 2011-12-14 重庆大学 一种评价血液及其代用品携氧、释氧功能的分析方法及装置
WO2009043031A2 (en) * 2007-09-27 2009-04-02 Children's Medical Center Corporation Microbubbles and methods for oxygen delivery
DK3266463T3 (da) 2009-06-09 2024-01-08 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US9114109B2 (en) * 2009-06-16 2015-08-25 University of Pittsburgh—of the Commonwealth System of Higher Education Five-coordinate neuroglobin and use thereof as a blood substitute
US8273857B2 (en) * 2009-09-22 2012-09-25 Jen-Chang Hsia Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine
US20130041134A1 (en) * 2009-11-05 2013-02-14 Sangart ,Inc. Methods for preparing polyethylene glycol maleimide using n-(2-hydroxyethyl) maleimide as a starting material
US9493616B2 (en) 2010-02-25 2016-11-15 Sangart, Inc. Methods for preparing PEG-hemoglobin conjugates using reduced reactant ratios
US7989593B1 (en) 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
US8048856B1 (en) 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
EP2661275B1 (en) * 2011-01-07 2019-01-02 Poseida Therapeutics, Inc. Compositions and methods for delivery of high-affinity oxygen binding agents to tumors
US20120196270A1 (en) * 2011-02-02 2012-08-02 Sangart, Inc. Methods for preserving an organ for transplantation using a hemoglobin-carbon monoxide complex
US8889830B2 (en) 2011-03-01 2014-11-18 Chuo University Hemoglobin-albumin complex, and artificial plasma expander and artificial oxygen carrier containing the complex
US8084581B1 (en) 2011-04-29 2011-12-27 Bing Lou Wong Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
US20130052232A1 (en) 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
JP6389125B2 (ja) * 2011-11-07 2018-09-12 ザ ジェネラル ホスピタル コーポレイション 赤血球の処理法
MX358785B (es) * 2012-03-29 2018-09-04 Sangart Inc Hemoglobina pegilada reticulada con diaspirina.
CA2908238C (en) 2012-04-03 2023-01-10 Schindler, William Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins
WO2013151682A1 (en) 2012-04-06 2013-10-10 Children's Medical Center Corporation Process for forming microbubbles with high oxygen content and uses thereof
CA2897018C (en) 2013-01-07 2021-07-27 Omniox, Inc. Polymeric forms of h-nox proteins
US10577554B2 (en) 2013-03-15 2020-03-03 Children's Medical Center Corporation Gas-filled stabilized particles and methods of use
WO2014145755A1 (en) * 2013-03-15 2014-09-18 Sangart, Inc. Polyalkylene oxide valerate hemoglobin conjugates
JP7049832B2 (ja) 2015-03-17 2022-04-07 オムニオクス， インコーポレイテッド タンパク質媒介性ｏ２送達による腫瘍免疫のモジュレーション
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
CN105497894B (zh) * 2015-12-21 2019-01-04 中国科学院深圳先进技术研究院 用于肿瘤光动力治疗的血红蛋白-光敏剂试剂及其应用
SG10202007517TA (en) 2016-02-16 2020-09-29 Omniox Inc Modulation of hypoxia associated with stroke
ES2865481T3 (es) 2016-04-29 2021-10-15 Poseida Therapeutics Inc Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos
EP3508214A4 (en) 2016-07-06 2020-05-13 Chuo University Therapeutic agent for ischemic diseases
ES2651717B1 (es) * 2016-07-26 2018-11-16 Lara OLLER DUQUE Solución acuosa cristaloide isotónica
WO2018160752A1 (en) 2017-02-28 2018-09-07 Children's Medical Center Corporation Stimuli-responsive particles encapsulating a gas and methods of use
EP3836911A1 (en) 2018-08-15 2021-06-23 Omniox, Inc. H-nox proteins for treating cardiovascular and pulmonary conditions
WO2021261712A1 (en) 2020-06-26 2021-12-30 Sunbio, Inc. Hemoglobin derivative co-conjugated with fatty acid-linked peg and alkoxy peg as a blood substitute
WO2024112490A2 (en) * 2022-10-27 2024-05-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitrosyl-heme formulations for the treatment cardiovascular conditions, hemolysis, and the stabilization of cell-free heme molecules

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507146A (en) 1968-02-09 1970-04-21 Webb James E Method and system for respiration analysis
US3956259A (en) 1973-01-30 1976-05-11 Baxter Laboratories, Inc. Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate
US3925344A (en) * 1973-04-11 1975-12-09 Community Blood Council Plasma protein substitute
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2430898A1 (de) 1974-06-27 1976-01-08 Clevert Hans Dietmar Doppelkapillar-oxygenator
DE2449885C3 (de) 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4061736A (en) * 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4001200A (en) 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4053590A (en) 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
GB1578776A (en) 1976-06-10 1980-11-12 Univ Illinois Hemoglobin liposome and method of making the same
JPS5329908A (en) 1976-08-27 1978-03-20 Green Cross Corp:The Immobilized haptoglobin preparation
US4209300A (en) 1978-09-25 1980-06-24 The United States Of America As Represented By The Department Of Health, Education And Welfare Hemoglobin-oxygen equilibrium curve analyzer
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5716815A (en) 1980-07-02 1982-01-28 Ajinomoto Co Inc Oxygen transporting agent for artificial blood
US4401652A (en) 1980-12-31 1983-08-30 Allied Corporation Process for the preparation of stroma-free hemoglobin solutions
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4532130A (en) 1981-07-06 1985-07-30 Rush-Presbyterian-St. Luke's Medical Center Preparation of synthetic frythrocytes
DE3130770C2 (de) 1981-08-04 1986-06-19 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Gewinnung von hepatitissicheren, sterilen, pyrogenfreien und stromafreien Hämoglobinlösungen
US4473496A (en) * 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
DE3144705C2 (de) 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
CH650647A5 (de) * 1982-12-10 1985-08-15 Knorr Naehrmittel Ag Lagerfaehiges, zu einer dessert-mousse aufschlagbares produkt und verfahren zu dessen herstellung.
US4473494A (en) 1983-05-04 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Preparation of stroma-free, non-heme protein-free hemoglobin
US4529719A (en) * 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
GB8328917D0 (en) 1983-10-28 1983-11-30 Fisons Plc Blood substitute
US5281579A (en) 1984-03-23 1994-01-25 Baxter International Inc. Purified virus-free hemoglobin solutions and method for making same
US4831012A (en) 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
DE3412144A1 (de) 1984-03-31 1985-10-10 Biotest Pharma GmbH, 6000 Frankfurt Verfahren zur herstellung hochgereinigter, stromafreier, hepatitissicherer human- und tierhaemoglobinloesungen
US4738952A (en) 1984-04-27 1988-04-19 Synthetic Blood Corporation Substitute for human blood and a method of making the same
US4598064A (en) 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4600531A (en) * 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4584130A (en) 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
US4987154A (en) 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
US5080885A (en) 1986-01-14 1992-01-14 Alliance Pharmaceutical Corp. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US5684050A (en) 1986-01-24 1997-11-04 Hemagen/Pfc Stable emulsions of highly fluorinated organic compounds
US5194590A (en) * 1986-06-20 1993-03-16 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5464814A (en) 1986-06-20 1995-11-07 Northfield Laboratories, Inc. Acellular red blood cell substitute
US4826811A (en) 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
DE3620873A1 (de) 1986-06-21 1987-12-23 Rau Guenter Vorrichtung zur bestimmung des partialdruckes von in einem fluid geloesten gasen und gasgemischen
US4911929A (en) 1986-08-29 1990-03-27 The United States Of America As Represented By The Secretary Of The Navy Blood substitute comprising liposome-encapsulated hemoglobin
DE3636590A1 (de) 1986-10-28 1988-05-26 Braun Melsungen Ag Blutersatzmittel
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
US5084558A (en) 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
GB8710598D0 (en) * 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
US5449759A (en) 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
US4861867A (en) 1988-02-03 1989-08-29 Baxter International, Inc. Purified hemoglobin solutions and method for making same
US4901727A (en) 1988-05-05 1990-02-20 The Boc Group, Inc. Micro-probe for gas sampling
US4900780A (en) 1988-05-25 1990-02-13 Masonic Medical Research Laboratory Acellular resuscitative fluid
JPH07113599B2 (ja) 1988-07-29 1995-12-06 三菱石油株式会社 流動液体中の気泡含有量の動的定量装置
CA1338244C (en) 1988-08-17 1996-04-09 Xiang-Fu Wu Purification of hemoglobin and methemoglobin by bioselective elution
US5061688A (en) 1988-08-19 1991-10-29 Illinois Institute Of Technology Hemoglobin multiple emulsion
IL87707A (en) 1988-09-08 1994-06-24 Technion Inst For Research And Hemoglobin-based blood substitute substantially similar to human blood and method for preparation thereof
US5128452A (en) 1989-04-19 1992-07-07 Baxter International Inc. Process for the production of crosslinked hemoglobin in the presence of sodium tripolyphosphate
NL8901174A (nl) 1989-05-10 1990-12-03 Het Hoofd Van De Afdeling Mili Hemoglobine-preparaat en gebruik daarvan.
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5599907A (en) 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
US5650388A (en) 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5478806A (en) 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
US5386014A (en) 1989-11-22 1995-01-31 Enzon, Inc. Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute
US5234903A (en) 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5041615A (en) 1989-12-05 1991-08-20 Baxter International Inc. Preparation of bis(salicyl) diesters
US5239061A (en) 1990-06-20 1993-08-24 Research Corporation Technologies, Inc. Modified human hemoglobin, blood substitutes containing the same, and vectors for expressing the modified hemoglobin
US5352773A (en) 1990-08-06 1994-10-04 Baxter International Inc. Stable hemoglobin based composition and method to store same
US5248766A (en) 1990-08-17 1993-09-28 Baxter International Inc. Oxirane-modified hemoglobin based composition
IT1244609B (it) 1990-09-14 1994-08-08 Instrumentation Lab Spa Procedimento ed apparecchiatura per la determinazione elettrochimica di specie gassose o volatili con particolare riferimento ad emogsanalizzatori.
US5114932A (en) 1990-11-30 1992-05-19 Runge Thomas M Hyperosmolar oxyreplete hemosubstitute
US5234555A (en) * 1991-02-05 1993-08-10 Ibbott Jack Kenneth Method and apparatus for ionizing fluids utilizing a capacitive effect
CA2066374C (en) 1991-04-19 2002-01-29 Paul E. Segall Solution for perfusing primates
US5295944A (en) 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
US5250665A (en) * 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US5334705A (en) 1991-08-15 1994-08-02 Duke University Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin
US5349054A (en) 1991-08-15 1994-09-20 Duke University Activated benzenepentacarboxylate-crosslinked low oxygen affinity hemoglobin
US5334706A (en) 1992-01-30 1994-08-02 Baxter International Administration of low dose hemoglobin to increase perfusion
US5200323A (en) 1992-01-31 1993-04-06 Mcgill University In vitro method to determine the safety of modified hemoglobin blood substitutes for human prior to clinical use
US5296466A (en) 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5344393A (en) 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US5264555A (en) 1992-07-14 1993-11-23 Enzon, Inc. Process for hemoglobin extraction and purification
US5628930A (en) 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US5558855A (en) 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
ATE146189T1 (de) 1993-03-16 1996-12-15 Hemosol Inc Selektive vernetzung von hemoglobin mittels oxidierten, ringgeöffneten sacchariden
US5635538A (en) 1993-03-16 1997-06-03 Alliance Pharmaceutical Corp. Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
US5554638A (en) 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5612310A (en) * 1993-05-24 1997-03-18 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5407428A (en) 1993-06-04 1995-04-18 Biotime, Inc. Solutions for use as plasma expanders and substitutes
PT701455E (pt) 1993-06-04 2001-09-27 Biotime Inc Solucao semelhante a plasma
US5578564A (en) 1993-07-23 1996-11-26 Somatogen, Inc. Nickel-free hemoglobin and methods for producing such hemoglobin
TW381022B (en) 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
CA2106612C (en) 1993-09-21 2001-02-06 Diana Pliura Displacement chromatography process
US5545328A (en) 1993-09-21 1996-08-13 Hemosol Inc. Purification of hemoglobin by displacement chromatography
US5631219A (en) 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US5585484A (en) * 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
US5525630A (en) 1995-06-01 1996-06-11 Allos Therapeutics, Inc. Treatment for carbon monoxide poisoning
US5814601A (en) * 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
AU735799C (en) * 1997-02-28 2005-04-28 Regents Of The University Of California, The Methods and compositions for optimisation of oxygen transport by cell-free systems
WO1999021002A1 (en) 1997-10-17 1999-04-29 The Regents Of The University Of California System and method to characterize gas transport properties
US5985825A (en) 1998-02-28 1999-11-16 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
CA2233725A1 (en) * 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
AU2003202941A1 (en) * 2002-01-11 2003-07-30 Sangart, Inc. Methods and compositions for oxygen transport comprising an oxygen carrier and a crystalloid in hypertonic solution
WO2003059286A2 (en) * 2002-01-11 2003-07-24 Sangart, Inc. Methods and compositions for oxygen transport comprising modified hemoglobin in plasma
ES2360215T3 (es) * 2002-12-23 2011-06-01 Albert Einstein College Of Medicine Of Yeshiva University Hemoglobinas pegiladas no hipertensivas y sus procedimientos de preparación.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112188865A (zh) * 2018-05-11 2021-01-05 斯佩克卓尼克斯股份有限公司 异常血氧合水平监测系统和方法及自监测氧合系统和方法
CN111499732A (zh) * 2020-04-22 2020-08-07 中国科学院过程工程研究所 一种基于双重化学修饰的血红蛋白氧载体及其制备方法和应用
CN111499732B (zh) * 2020-04-22 2022-05-13 中国科学院过程工程研究所 一种基于双重化学修饰的血红蛋白氧载体及其制备方法和应用
CN114617957A (zh) * 2022-03-10 2022-06-14 中国人民解放军军事科学院军事医学研究院 羟乙基淀粉血红蛋白偶联物及其制备方法与应用
CN114617957B (zh) * 2022-03-10 2024-01-16 中国人民解放军军事科学院军事医学研究院 羟乙基淀粉血红蛋白偶联物及其制备方法与应用

Also Published As

Publication number Publication date
KR20040081451A (ko) 2004-09-21
ES2299686T3 (es) 2008-06-01
US20030162693A1 (en) 2003-08-28
DK1465643T3 (da) 2008-05-13
CA2473662C (en) 2009-12-22
EP1465643B1 (en) 2008-01-02
CA2473662A1 (en) 2003-07-24
ATE382358T1 (de) 2008-01-15
KR100964604B1 (ko) 2010-06-21
JP2005515225A (ja) 2005-05-26
DE60318388D1 (de) 2008-02-14
WO2003059363A1 (en) 2003-07-24
JP5149480B2 (ja) 2013-02-20
JP2010138197A (ja) 2010-06-24
US6974795B2 (en) 2005-12-13
EP1465643A1 (en) 2004-10-13
DE60318388T2 (de) 2008-12-24
MXPA04006733A (es) 2005-12-05
US20030153491A1 (en) 2003-08-14
US20050026816A1 (en) 2005-02-03
PT1465643E (pt) 2008-03-27
AU2003207504B2 (en) 2007-05-24
BR0306846A (pt) 2004-12-07
CN1630527B (zh) 2013-04-24
US6844317B2 (en) 2005-01-18
CN1630527A (zh) 2005-06-22
AU2003207504A1 (en) 2003-07-30
EP1465643A4 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
CN103203013A (zh) 包含高氧亲和力的修饰血红蛋白的氧气输送方法和组合物
US9241979B2 (en) Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US8278275B2 (en) Method to enhance hemodynamic stability using oxygen carrying compositions
EP1894573A2 (en) Methods and compositions for oxygen transport comprising a high oxygen affinity
WO2003059287A2 (en) Methods and compositions for oxygen transport comprising an oxygen carrier and a crystalloid in hypertonic solution

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130717